CCXI ChemoCentryx, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

CCXI [NASD]

ChemoCentryx, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	4.20%	Shs Outstand	63.28M	Perf Week	0.38%
Market Cap	3.37B	Forward P/E	-	EPS next Y	-1.40	Insider Trans	-42.04%	Shs Float	52.44M	Perf Month	-2.41%
Income	-29.80M	PEG	-	EPS next Q	-0.31	Inst Own	77.70%	Short Float	10.44%	Perf Quarter	-4.69%
Sales	76.10M	P/S	44.22	EPS this Y	-28.00%	Inst Trans	0.64%	Short Ratio	9.47	Perf Half Y	-1.45%
Book/sh	6.65	P/B	7.86	EPS next Y	-91.80%	ROA	-10.30%	Target Price	76.75	Perf Year	514.59%
Cash/sh	7.83	P/C	6.67	EPS next 5Y	-	ROE	-19.60%	52W Range	7.61 - 65.43	Perf YTD	32.09%
Dividend	-	P/FCF	-	EPS past 5Y	2.10%	ROI	-68.00%	52W High	-20.16%	Beta	1.69
Dividend %	-	Quick Ratio	9.00	Sales past 5Y	-	Gross Margin	-	52W Low	586.47%	ATR	3.12
Employees	82	Current Ratio	9.00	Sales Q/Q	586.10%	Oper. Margin	-41.50%	RSI (14)	43.29	Volatility	8.04% 5.39%
Optionable	Yes	Debt/Eq	0.06	EPS Q/Q	211.90%	Profit Margin	-39.20%	Rel Volume	1.01	Prev Close	52.44
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Aug 10 AMC	Payout	-	Avg Volume	578.40K	Price	52.24
Recom	1.50	SMA20	-7.44%	SMA50	-2.77%	SMA200	1.55%	Volume	584,500	Change	-0.37%

Jun-17-20

Initiated

BTIG Research

Buy

$70

May-27-20

Initiated

Wells Fargo

Overweight

$79

May-12-20

Reiterated

H.C. Wainwright

Buy

$60 → $69

Jan-24-20

Reiterated

H.C. Wainwright

Buy

$40 → $60

Nov-26-19

Reiterated

Piper Jaffray

Overweight

$17 → $54

Nov-26-19

Reiterated

H.C. Wainwright

Buy

$23 → $40

Mar-27-19

Upgrade

B. Riley FBR

Neutral → Buy

$12.50 → $22

Feb-11-19

Initiated

Piper Jaffray

Overweight

$20

Sep-07-18

Initiated

B. Riley FBR

Neutral

$12.50

Aug-14-18

Downgrade

JP Morgan

Overweight → Neutral

Jun-28-18

Initiated

Raymond James

Strong Buy

May-02-18

Initiated

H.C. Wainwright

Buy

$20

Feb-21-17

Initiated

JMP Securities

Mkt Outperform

May-18-15

Upgrade

JP Morgan

Neutral → Overweight

May-20-13

Reiterated

Stifel

Buy

$16 → $20

Nov-14-12

Initiated

Stifel Nicolaus

Buy

$16

Oct-28-20 04:01PM	ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS) GlobeNewswire
Oct-26-20 12:31PM	Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for Zacks -9.52%
Oct-19-20 08:03AM	Despite Lacking Profits ChemoCentryx (NASDAQ:CCXI) Seems To Be On Top Of Its Debt Simply Wall St. -5.60%
Sep-18-20 10:56AM	ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA Zacks +5.21%
Sep-17-20 08:30AM	ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis GlobeNewswire
Sep-15-20 12:47AM	Hedge Funds Arent Done Buying ChemoCentryx Inc (CCXI) Insider Monkey
Sep-08-20 08:30AM	ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Sep-04-20 08:45AM	Imagine Holding ChemoCentryx (NASDAQ:CCXI) Shares While The Price Zoomed 652% Higher Simply Wall St.
Aug-11-20 04:31PM	ChemoCentryx Inc (CCXI) Q2 2020 Earnings Call Transcript Motley Fool
10:00AM	Tencents China Literature Crashes to $465 Million Loss Variety
Aug-10-20 05:45PM	ChemoCentryx (CCXI) Q2 Earnings and Revenues Surpass Estimates Zacks
04:05PM	ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
Aug-04-20 08:30AM	ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-03-20 08:30AM	ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020 GlobeNewswire
Jul-27-20 12:31PM	Earnings Preview: ChemoCentryx (CCXI) Q2 Earnings Expected to Decline Zacks
Jul-21-20 06:37AM	How Much is ChemoCentryx's (NASDAQ:CCXI) CEO Getting Paid? Simply Wall St.
Jul-17-20 11:02AM	Insiders Roundup: Mastercard, ChemoCentryx GuruFocus.com
Jul-13-20 10:43AM	Did Hedge Funds Make The Right Call On ChemoCentryx Inc (CCXI) ? Insider Monkey -5.24%
Jul-10-20 11:11AM	Insiders Roundup: Mastercard, Eli Lilly GuruFocus.com
Jul-09-20 08:30AM	ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis GlobeNewswire
Jul-07-20 11:14AM	3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap TipRanks
08:50AM	Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock? Zacks
Jun-29-20 12:53PM	Top Small Cap Stocks for July 2020 Investopedia
Jun-24-20 08:30AM	ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment GlobeNewswire
Jun-15-20 10:34PM	Edited Transcript of CCXI.OQ earnings conference call or presentation 11-May-20 9:00pm GMT Thomson Reuters StreetEvents
04:05PM	ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Jun-12-20 09:49AM	Hedge Funds Have Never Been This Bullish On ChemoCentryx Inc (CCXI) Insider Monkey +12.11%
Jun-10-20 09:33PM	ChemoCentryx Prices Public Offering of Common Stock GlobeNewswire
04:08PM	ChemoCentryx Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-03-20 07:30AM	ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses GlobeNewswire
May-18-20 08:30AM	ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire +8.72%
May-16-20 10:49AM	Analysts Have Just Cut Their ChemoCentryx, Inc. (NASDAQ:CCXI) Revenue Estimates By 11% Simply Wall St.
May-14-20 06:53AM	ChemoCentryx, Inc. (NASDAQ:CCXI) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-12-20 01:30PM	ChemoCentryx Inc (CCXI) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 07:55PM	ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
07:00AM	Is There An Opportunity With ChemoCentryx, Inc.'s (NASDAQ:CCXI) 47% Undervaluation? Simply Wall St.
May-04-20 08:30AM	ChemoCentryx to Hold First Quarter 2020 Financial Results Conference Call on Monday, May 11, 2020 GlobeNewswire +6.27%
Apr-27-20 12:31PM	Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-22-20 12:00PM	Here's Why Momentum Investors Will Love ChemoCentryx (CCXI) Zacks
Apr-07-20 12:00PM	ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-05-20 01:17AM	Edited Transcript of CCXI earnings conference call or presentation 10-Mar-20 9:00pm GMT Thomson Reuters StreetEvents
Mar-31-20 04:52PM	5 Guru Stocks That Beat the Market GuruFocus.com
Mar-16-20 09:47AM	Why ChemoCentryx (CCXI) Stock Might be a Great Pick Zacks -22.52%
Mar-12-20 07:00AM	ChemoCentryx, Inc. Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates Simply Wall St. -5.90%
Mar-10-20 05:25PM	ChemoCentryx (CCXI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights GlobeNewswire
03:00PM	ChemoCentryx, Inc. to Host Earnings Call ACCESSWIRE
Mar-03-20 08:30AM	ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020 GlobeNewswire
Mar-02-20 12:30PM	ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Feb-19-20 08:30AM	ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-10-20 06:00PM	Biotechs punch up talking points leading into big Union Square conference American City Business Journals
05:01AM	Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 423% Share Price Gain? Simply Wall St.
Jan-09-20 08:30AM	ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital GlobeNewswire
Jan-08-20 08:30AM	ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference GlobeNewswire
Dec-11-19 03:58PM	Hedge Funds Dropped The Ball On ChemoCentryx Inc (CCXI) Insider Monkey
Dec-01-19 09:30AM	The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-29-19 11:24AM	The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
Nov-28-19 09:00AM	ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Nov-27-19 10:15AM	Company News For Nov 27, 2019 Zacks
10:09AM	Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
08:52AM	ChemoCentryx Up on Encouraging Rare Disease Candidate Data Zacks
07:26AM	The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
07:23AM	Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease MarketWatch
Nov-26-19 02:03PM	ChemoCentryx (CCXI) Stock Could Hit $40, Says Analyst TipRanks +281.27%
10:07AM	These stocks and ETFs will help investors survive a not great year, says top Wall Street strategist MarketWatch
08:42AM	Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 26, 2019: BBY, CCXI, PANW, DLTR, DE Benzinga
08:30AM	ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
08:14AM	Dow Jones Futures: Palo Alto Networks Dives, Nutanix Soars; This Biotech Quadruples Investor's Business Daily
08:06AM	The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
07:00AM	Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries Market Exclusive
01:00AM	VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA Associated Vasculitis TEST Business Wire Releases
01:00AM	VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA Associated Vasculitis Business Wire
Nov-25-19 06:11PM	ChemoCentryx stock quadruples after 'transformational' vasculitis study MarketWatch
04:05PM	ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopans Superiority Over Standard of Care in ANCA-Associated Vasculitis GlobeNewswire
08:54AM	Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock? Zacks
Nov-20-19 05:32PM	Plans filed for massive biotech campus in San Carlos American City Business Journals
Nov-17-19 02:41AM	Edited Transcript of CCXI earnings conference call or presentation 4-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-11-19 08:33AM	How Should Investors React To ChemoCentryx, Inc.'s (NASDAQ:CCXI) CEO Pay? Simply Wall St.
Nov-05-19 08:30AM	Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire +6.84%
Nov-04-19 06:45PM	ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Oct-30-19 06:59PM	ChemoCentryx Inc (CCXI) Is Burning These Hedge Funds Insider Monkey +5.65%
Oct-28-19 08:30AM	ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019 GlobeNewswire
Sep-24-19 08:30AM	ChemoCentryx to Host R&D Day on October 1, 2019 GlobeNewswire
Aug-29-19 08:30AM	ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-17-19 06:09AM	Edited Transcript of CCXI earnings conference call or presentation 5-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 10:19AM	ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-05-19 07:25PM	ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM	ChemoCentryx Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Aug-02-19 05:48PM	Longtime biotech to move up Peninsula to Alexandria's big San Carlos project American City Business Journals
Aug-01-19 08:30AM	ChemoCentryx to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-31-19 08:30AM	ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 GlobeNewswire
Jun-11-19 08:30AM	ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Jun-06-19 07:37AM	The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
May-20-19 09:00AM	ChemoCentryx (CCXI) Moves to Buy: Rationale Behind the Upgrade Zacks
May-11-19 02:05PM	Edited Transcript of CCXI earnings conference call or presentation 6-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-09-19 11:07AM	Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) Insider Monkey
May-07-19 01:29AM	ChemoCentryx Inc (CCXI) Q1 2019 Earnings Call Transcript Motley Fool
May-06-19 06:15PM	ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates Zacks

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vifor (International) Ltd	10% Owner	Aug 03	Sale	53.93	49,258	2,656,655	9,194,085	Aug 03 07:10 PM
Vifor (International) Ltd	10% Owner	Jul 31	Sale	52.39	40,402	2,116,825	9,243,343	Aug 03 07:10 PM
Vifor (International) Ltd	10% Owner	Jul 30	Sale	54.60	48,081	2,625,330	9,283,745	Aug 03 07:10 PM
Vifor (International) Ltd	10% Owner	Jul 29	Sale	52.58	88,012	4,627,479	9,331,826	Jul 29 07:55 PM
Vifor (International) Ltd	10% Owner	Jul 28	Sale	53.51	40,160	2,149,117	9,419,838	Jul 29 07:55 PM
Vifor (International) Ltd	10% Owner	Jul 27	Sale	53.32	34,236	1,825,476	9,459,998	Jul 29 07:55 PM
Vifor (International) Ltd	10% Owner	Jul 24	Sale	52.54	26,050	1,368,737	9,494,234	Jul 24 07:53 PM
Vifor (International) Ltd	10% Owner	Jul 23	Sale	54.15	34,555	1,871,297	9,520,284	Jul 24 07:53 PM
Vifor (International) Ltd	10% Owner	Jul 22	Sale	55.58	72,469	4,027,868	9,554,839	Jul 24 07:53 PM
Vifor (International) Ltd	10% Owner	Jul 21	Sale	55.50	87,529	4,857,632	9,627,308	Jul 21 06:32 PM
Vifor (International) Ltd	10% Owner	Jul 20	Sale	56.03	54,598	3,059,053	9,714,837	Jul 21 06:32 PM
Vifor (International) Ltd	10% Owner	Jul 17	Sale	55.86	47,890	2,675,105	9,769,435	Jul 21 06:32 PM
Vifor (International) Ltd	10% Owner	Jul 16	Sale	56.96	73,500	4,186,741	9,817,325	Jul 16 08:00 PM
Vifor (International) Ltd	10% Owner	Jul 15	Sale	59.22	86,298	5,110,971	9,890,825	Jul 16 08:00 PM
Vifor (International) Ltd	10% Owner	Jul 14	Sale	58.08	100,000	5,808,318	9,977,123	Jul 16 08:00 PM
Vifor (International) Ltd	10% Owner	Jul 13	Sale	58.15	100,000	5,815,027	10,077,123	Jul 13 07:18 PM
Vifor (International) Ltd	10% Owner	Jul 10	Sale	59.92	45,844	2,747,172	10,177,123	Jul 13 07:18 PM
Vifor (International) Ltd	10% Owner	Jul 09	Sale	59.91	100,000	5,990,521	10,222,967	Jul 13 07:18 PM
Vifor (International) Ltd	10% Owner	Jul 08	Sale	59.95	100,000	5,994,745	10,322,967	Jul 08 08:39 PM
Vifor (International) Ltd	10% Owner	Jul 07	Sale	59.21	79,387	4,700,838	10,422,967	Jul 08 08:39 PM
Vifor (International) Ltd	10% Owner	Jul 06	Sale	58.44	86,690	5,066,120	10,502,354	Jul 08 08:39 PM
Vifor (International) Ltd	10% Owner	Jul 02	Sale	57.47	87,781	5,044,434	10,589,044	Jul 07 06:57 PM
Schall Thomas J.	President and CEO	Jun 15	Option Exercise	14.31	2,000	28,620	2,270,557	Jun 16 08:20 PM
Schall Thomas J.	President and CEO	Jun 15	Sale	65.04	2,000	130,090	2,268,557	Jun 16 08:20 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jun 12	Option Exercise	10.86	33,541	364,255	109,788	Jun 16 08:02 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jun 12	Option Exercise	9.32	50,000	466,100	141,317	Jun 16 08:08 PM
Schall Thomas J.	President and CEO	Jun 12	Option Exercise	14.31	88,753	1,270,055	2,357,310	Jun 16 08:20 PM
Schall Thomas J.	President and CEO	Jun 12	Sale	65.08	88,753	5,775,877	2,268,557	Jun 16 08:20 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jun 12	Sale	64.58	50,000	3,229,035	91,317	Jun 16 08:08 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jun 12	Sale	65.10	33,541	2,183,519	76,247	Jun 16 08:02 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jun 03	Option Exercise	5.31	10,750	57,059	104,930	Jun 05 07:11 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 26	Option Exercise	6.62	19,612	129,831	95,859	May 26 09:04 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 26	Sale	60.34	19,612	1,183,423	76,247	May 26 09:04 PM
Tyree James L	Director	May 23	Option Exercise	0.00	7,724	0	13,069	May 26 08:59 PM
Parker Geoffrey M.	Director	May 23	Option Exercise	0.00	7,724	0	111,913	May 26 08:55 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 22	Option Exercise	6.62	40,867	270,540	117,114	May 26 09:04 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 22	Sale	60.06	40,867	2,454,525	76,247	May 26 09:04 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 21	Option Exercise	6.62	2,800	18,536	79,047	May 26 09:04 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 21	Sale	60.00	2,800	167,986	76,247	May 26 09:04 PM
Schall Thomas J.	President and CEO	May 12	Option Exercise	14.31	35,865	513,228	2,304,422	May 12 07:50 PM
Schall Thomas J.	President and CEO	May 12	Sale	57.75	35,865	2,071,100	2,268,557	May 12 07:50 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 11	Option Exercise	3.57	34,222	122,173	110,469	May 12 07:45 PM
Schall Thomas J.	President and CEO	May 11	Option Exercise	14.31	70,608	1,010,400	2,339,165	May 12 07:50 PM
Schall Thomas J.	President and CEO	May 11	Sale	55.51	70,608	3,919,731	2,268,557	May 12 07:50 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 11	Sale	55.11	34,222	1,886,135	76,247	May 12 07:45 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 08	Option Exercise	3.57	4,312	15,394	80,559	May 12 07:45 PM
Schall Thomas J.	President and CEO	May 08	Option Exercise	14.31	4,201	60,116	2,272,758	May 12 07:50 PM
Schall Thomas J.	President and CEO	May 08	Sale	55.01	4,201	231,115	2,268,557	May 12 07:50 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 08	Sale	50.01	4,312	215,639	76,247	May 12 07:45 PM
Schall Thomas J.	President and CEO	May 05	Option Exercise	14.31	8,851	126,658	2,277,408	May 07 08:11 PM
KANAYA SUSAN M	EVP, CFO and Sec.	May 05	Option Exercise	8.19	20,123	164,807	111,440	May 06 08:19 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 05	Option Exercise	3.57	8,860	31,630	85,107	May 07 07:59 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	May 05	Sale	55.01	8,860	487,345	76,247	May 07 07:59 PM
KANAYA SUSAN M	EVP, CFO and Sec.	May 05	Sale	54.73	20,123	1,101,237	91,317	May 06 08:19 PM
Schall Thomas J.	President and CEO	May 05	Sale	55.01	8,851	486,851	2,268,557	May 07 08:11 PM
KANAYA SUSAN M	EVP, CFO and Sec.	May 04	Option Exercise	8.19	54,877	449,443	146,194	May 06 08:19 PM
KANAYA SUSAN M	EVP, CFO and Sec.	May 04	Sale	54.57	54,877	2,994,819	91,317	May 06 08:19 PM
Jain Rita	Director	Mar 27	Option Exercise	0.00	5,251	0	12,975	Mar 31 07:10 PM
Parker Geoffrey M.	Director	Mar 23	Sale	36.70	30,000	1,101,049	49,600	Mar 25 06:42 PM
Schall Thomas J.	President and CEO	Mar 04	Option Exercise	14.31	40,844	584,478	2,309,401	Mar 05 07:03 PM
Schall Thomas J.	President and CEO	Mar 04	Sale	50.35	40,844	2,056,691	2,268,557	Mar 05 07:03 PM
Schall Thomas J.	President and CEO	Feb 20	Option Exercise	14.31	15,341	219,530	2,283,898	Feb 21 07:24 PM
Schall Thomas J.	President and CEO	Feb 20	Sale	50.21	15,341	770,296	2,268,557	Feb 21 07:24 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 19	Option Exercise	8.19	42,631	349,148	118,878	Feb 21 07:05 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 19	Option Exercise	10.86	24,200	262,812	118,380	Feb 21 07:15 PM
Schall Thomas J.	President and CEO	Feb 19	Option Exercise	14.31	63,340	906,395	2,331,897	Feb 21 07:24 PM
Schall Thomas J.	President and CEO	Feb 19	Sale	50.50	63,340	3,198,514	2,268,557	Feb 21 07:24 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 19	Sale	50.13	24,200	1,213,221	94,180	Feb 21 07:15 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 19	Sale	50.36	42,631	2,146,698	76,247	Feb 21 07:05 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 13	Option Exercise	9.76	45,300	442,029	139,480	Feb 13 08:00 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 13	Sale	49.61	45,300	2,247,147	94,180	Feb 13 08:00 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 12	Option Exercise	9.69	2,500	24,213	96,680	Feb 13 08:00 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 12	Sale	49.51	2,500	123,776	94,180	Feb 13 08:00 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 11	Option Exercise	10.68	3,000	32,046	97,180	Feb 13 08:00 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 11	Sale	49.50	3,000	148,510	94,180	Feb 13 08:00 PM
Kwan Pui San	Principal Acctg Officer	Feb 11	Sale	49.15	18,941	930,888	493	Feb 13 07:50 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 06	Option Exercise	8.19	36,850	301,802	113,097	Feb 10 07:53 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 06	Sale	47.31	36,850	1,743,340	76,247	Feb 10 07:53 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 05	Option Exercise	8.19	13,150	107,699	89,397	Feb 05 08:02 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 05	Sale	47.03	13,150	618,451	76,427	Feb 05 08:02 PM
Schall Thomas J.	President and CEO	Feb 04	Option Exercise	14.31	119,525	1,710,403	2,388,082	Feb 06 06:51 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 04	Option Exercise	14.31	99,617	1,425,519	193,797	Feb 05 08:32 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 04	Sale	45.10	99,617	4,492,229	94,180	Feb 05 08:32 PM
Schall Thomas J.	President and CEO	Feb 04	Sale	45.18	119,525	5,400,701	2,268,557	Feb 06 06:51 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 03	Option Exercise	8.19	48,471	396,977	124,718	Feb 05 08:02 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 03	Option Exercise	14.31	3,837	54,907	98,017	Feb 05 08:32 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Feb 03	Sale	44.91	3,837	172,317	94,180	Feb 05 08:32 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Feb 03	Sale	44.47	48,471	2,155,525	76,247	Feb 05 08:02 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 21	Option Exercise	8.19	1,259	10,311	77,506	Jan 23 07:31 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 21	Sale	44.00	1,259	55,392	76,247	Jan 23 07:31 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jan 17	Option Exercise	14.28	15,737	224,724	109,917	Jan 17 07:49 PM
Schall Thomas J.	President and CEO	Jan 17	Option Exercise	10.27	105,735	1,085,898	2,374,292	Jan 17 07:55 PM
Schall Thomas J.	President and CEO	Jan 17	Sale	41.60	105,735	4,398,272	2,268,557	Jan 17 07:55 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jan 17	Sale	41.03	15,737	645,730	94,180	Jan 17 07:49 PM
Kwan Pui San	Principal Acctg Officer	Jan 16	Option Exercise	8.31	89,179	740,881	108,613	Jan 17 07:36 PM
Cappel Markus J.	Chief Bus. Officer & Treasurer	Jan 16	Option Exercise	7.10	50,000	355,000	126,247	Jan 17 07:42 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jan 16	Option Exercise	14.28	47,261	674,887	141,441	Jan 17 07:49 PM
Schall Thomas J.	President and CEO	Jan 16	Option Exercise	10.27	30,317	311,356	2,298,874	Jan 17 07:55 PM
Schall Thomas J.	President and CEO	Jan 16	Sale	41.01	30,317	1,243,170	2,268,557	Jan 17 07:55 PM
KANAYA SUSAN M	EVP, CFO and Sec.	Jan 16	Sale	40.99	47,261	1,937,101	94,180	Jan 17 07:49 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience